Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474915 · ClinicalTrials.gov registry record · Phase 4
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
A Phase 4 study of Nausea and Post-operative Nausea and Vomiting (PONV), sponsored by Sergio Bergese.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT01474915: Completed Phase 4 study of Nausea and Post-operative Nausea and Vomiting (PONV), sponsored by Sergio Bergese.
NCT01474915 is a Phase 4 study of Nausea and Post-operative Nausea and Vomiting (PONV) that has completed, run by Sergio Bergese. The registered enrollment target is 122 participants, below the 237-participant average among 17 other Nausea trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01474915, a Phase 4 study of Nausea and Post-operative Nausea and Vomiting (PONV), has completed, sponsored by Sergio Bergese.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine the efficacies of two preventative drug combinations for postoperative nausea and vomiting in patients undergoing neurosurgery. The aim of this study is to compare the efficacy of using aprepitant instead of ondansetron in combination with dexamethasone and promethazine for post-operative nausea and vomiting prophylaxis. By completing this comparison study investigators will determine the most efficacious drug combination which will allow us to enhance the overall comfort and satisfaction of neurosurgical patients in the immediate postoperative period.
Primary Outcome
To assess the efficacy of triple therapy with Scopolamine, Ondansetron and Dexamethasone for prevention of post operative nausea and vomiting (PONV) in high risk patients during the first 24 hours after neurological surgery under general anesthesia. \- Proportion of patients with a complete response/complete control during the first 24 hours after neurological surgery under general anesthesia. Complete Control is defined as no emetic episode, no need for rescue medication and no more than mild
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Ondansetron
- DRUG Aprepitant
- DRUG Promethazine
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT01474915 record still lists
NCT01474915 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 237-participant average among 17 other Nausea trials with a reported enrollment target (49% lower).
The record links to 2 conditions, with Nausea appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01474915 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01474915 about?
NCT01474915 is a clinical study titled "Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting". This study is being done to determine the efficacies of two preventative drug combinations for postoperative nausea and vomiting in patients undergoing neurosurgery. The aim of this study is to compare the efficacy of using aprepitant instead of ondansetron in combination with dexamethasone and prom...
What is the current status of trial NCT01474915?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2007-06. Estimated completion is 2013-04.
What conditions does trial NCT01474915 study?
This clinical trial studies the following conditions: Nausea, Post-operative Nausea and Vomiting (PONV).
What interventions are being tested in trial NCT01474915?
The interventions under investigation include: Dexamethasone (DRUG), Ondansetron (DRUG), Aprepitant (DRUG), Promethazine (DRUG).
Who is sponsoring clinical trial NCT01474915?
This trial is sponsored by Sergio Bergese, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01474915 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01474915's enrollment target sits among peer trials
122 8th of 17 higher than 9 of 17 other Nausea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nausea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Montefiore Metoclopramide Study
COMPLETED · Phase 4
-
Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department
COMPLETED · Phase 4
-
Inhaled Isopropyl Alcohol for Treatment of Nausea
RECRUITING · Phase 2
-
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
RECRUITING · NA
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia